Autopsy report · NCT02705703

Consolidation Therapy in Patients With Metastatic Solid Malignancies

“Sponsor decision to discontinue study.”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 1, Phase 2

Sponsor

Kiromic BioPharma Inc.

Sponsor type

Industry

Conditions

Cancer; Metastatic Solid Malignancies

Interventions

TAPA-pulsed DC vaccine

Participants

0

Trials that died the same way

• Study of Brexucabtagene Autoleucel in Adults With Rare B-cell Malignancies
  “Sponsor decision to terminate study.” (90% match in meaning)
• Efficacy and Safety of Etrasimod (APD334) in Inflammatory Bowel Disease Patients With Active Skin Extra-intestinal Manifestations
  “Sponsor decision to terminate the study” (89% match in meaning)
• A Proof-of-Concept Study to Correlate Retinal Nerve Fiber Layer Changes in Patients With Multiple Sclerosis Treated With Natalizumab or Interferon Beta 1-a
  “Sponsor decision to withdraw study at this time.” (89% match in meaning)
• Safety and Efficacy of Medical Cannabis Oil in the Treatment of Patients with Chronic Pain
  “Sponsor decision to stop the study” (87% match in meaning)
• A Study of ABP 215 Versus Bevacizumab in Chinese Subjects With Advanced Non-Squamous Non-Small Cell Lung Cancer
  “Sponsor decision to early terminate the study” (87% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.